Physician profile
Jan Slezak
NPI 1750357307
$4,626.11
in general payments reported to CMS, 2019-2025
32 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $442 · 2021: $784 · 2022: $579 · 2023: $995 · 2024: $844 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $571.32 | 2019-2025 | Iovera, Exparel, Zilretta |
| Medtronic, INC. | $452.50 | 2021-2024 | Intellis Adaptivestim |
| Stryker Corporation | $403.44 | 2020-2024 | Motionsense Digital Goniometer, Spinejack |
| Pacira Therapeutics, INC. | $355.35 | 2019-2021 | |
| Abbott Laboratories | $336.22 | 2019-2023 | Proclaim |
| Nevro Corp. | $331.64 | 2019-2020 | |
| Bioventus LLC | $325.03 | 2022-2023 | Durolane |
| Skeletal Dynamics INC | $244.90 | 2024-2025 | Align, Implate, Geminus |
| Smith+Nephew, INC. | $235.52 | 2021-2023 | Evos, Trigen Intertan |
| Allergan, INC. | $175.75 | 2020-2022 | |
| Acumed LLC | $120.69 | 2021 | |
| Painteq LLC | $106.94 | 2024 | Painteq |
| Heraeus Medical, LLC. | $106.74 | 2024 | |
| Zimmer Biomet Holdings, INC. | $105.79 | 2019 | |
| Collegium Pharmaceutical, INC. | $92.86 | 2020-2024 | Belbuca |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $83.42 | 2021-2022 | |
| Boston Scientific Corporation | $80.62 | 2022-2023 | |
| Convatec INC. | $66.47 | 2020 | |
| Merz North America, INC. | $56.84 | 2020 | |
| Vertos Medical, INC. | $44.29 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $42.93 | 2019-2020 | |
| Medtronic USA, INC. | $40.12 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.24 | 2022 | |
| Djo, LLC | $35.04 | 2025 | Cmf |
| Biodelivery Sciences International, INC. | $35.00 | 2019-2021 | |
| Abbvie INC. | $34.00 | 2022 | |
| Nalu Medical, INC. | $28.72 | 2022 | |
| Almatica Pharma LLC | $22.19 | 2021 | |
| Pfizer INC. | $21.78 | 2023 | |
| Lilly USA, LLC | $16.97 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.79 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Slezak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.